Collin Hovinga

Collin Hovinga currently serves as the Vice President of Rare and Orphan Diseases at the Critical Path Institute, a position held since October 2022. Hovinga has extensive experience in drug safety and risk management as a member of the FDA's DSaRM Committee since June 2020. Academic contributions include a role as Clinical Associate Professor at The University of Texas at Austin, with research focused on pharmacotherapy outcomes across pediatric and adult populations. Previous leadership roles include Senior Vice President at the Institute for Advanced Clinical Trials for Children and Director of Research Support Services at Ascension Texas, where Hovinga directed research efforts across multiple hospitals. Hovinga holds multiple advanced degrees and fellowships, highlighting expertise in health outcomes, epidemiology, and clinical pharmacology.